SynthesisJournal of thrombosis and thrombolysis2026
Endovascular thrombectomy for acute stroke in anticoagulated patients: systematic review and Meta-Analysis.
Synthesis in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An umbrella review of systematic reviews and meta-analyses evaluating the efficacy and safety of mechanical thrombectomy for acute ischemic stroke.Annals of medicine and surgery (2012) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endovascular thrombectomy (EVT) is an effective treatment for acute ischemic stroke (AIS). Oral anticoagulants are used for stroke prevention in pro-embolic patients, but their impact on EVT outcomes, particularly symptomatic intracranial hemorrhage (sICH), remains uncertain. This study aims to evaluate the safety and efficacy of vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) on EVT outcomes. We searched PubMed, Cochrane, and Embase from 2015 to August 2024 for studies comparing anticoagulated and non-anticoagulated AIS patients undergoing EVT. Safety outcomes included sICH and 90 days mortality. Efficacy outcomes included successful reperfusion rate and 90 days functional outcome. Subgroup analyses evaluated the effect of therapeutic-dose anticoagulation. Fifteen studies with 62,328 AIS patients were included; 9,977 were anticoagulated (6,879 VKA, 3,098 DOAC). VKA patients had a significantly higher rate of sICH (OR = 1.32, 95% CI [1.05, 1.66]) and 90 days mortality (OR = 1.61, 95% CI [1.25, 2.08]) compared to non-anticoagulated patients. DOACs showed no significant difference in sICH risk (OR = 0.83, 95% CI [0.48, 1.44]) or mortality (OR = 1.20, 95% CI [0.89, 1.61]). Functional outcomes at 90 days were significantly worse in both anticoagulated groups, but only VKA patients demonstrated worsened outcomes in the therapeutic-dose subgroup analysis. EVT success rates were comparable between all groups. DOACs offer a safer EVT profile than VKAs, with lower sICH risk and mortality. These findings support DOACs as the preferred anticoagulant for stroke prevention. Further research should assess long-term outcomes and distinguish procedure-related mortality from secondary causes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.